Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies

Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies

Targeting cancer cells that are highly dependent on the nicotinamide adenine dinucleotide (NAD+) metabolite is a promising therapeutic strategy. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme catalyzing NAD<sup>+</sup> production. Despite the high efficacy of...

Full description

Bibliographic Details
Main Authors:	Paulina Biniecka, Saki Matsumoto, Axel Belotti, Jessie Joussot, Jian Fei Bai, Somi Reddy Majjigapu, Paul Thoueille, Dany Spaggiari, Vincent Desfontaine, Francesco Piacente, Santina Bruzzone, Michele Cea, Laurent A. Decosterd, Pierre Vogel, Alessio Nencioni, Michel A. Duchosal, Aimable Nahimana
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Series:	Molecules
Subjects:	NAMPT inhibitor NAD anticancer leukemia lymphoma multiple myeloma
Online Access:	https://www.mdpi.com/1420-3049/28/4/1897

Similar Items

Extracellular Nicotinamide Phosphoribosyltransferase Is a Component of the Senescence-Associated Secretory Phenotype
by: Chisaka Kuehnemann, et al.
Published: (2022-07-01)

Nicotinaldehyde, a Novel Precursor of NAD Biosynthesis, Abrogates the Anti-Cancer Activity of an NAD-Lowering Agent in Leukemia
by: Saki Matsumoto, et al.
Published: (2023-01-01)

Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery
by: Moustafa S. Ghanem, et al.
Published: (2022-07-01)

Nicotinamide Phosphoribosyltransferase as a Key Molecule of the Aging/Senescence Process
by: Fiqri D. Khaidizar, et al.
Published: (2021-04-01)

Nicotinamide Phosphoribosyltransferase (Nampt)/Nicotinamide Adenine Dinucleotide (NAD) Axis Suppresses Atrial Fibrillation by Modulating the Calcium Handling Pathway
by: Duo Feng, et al.
Published: (2020-06-01)

Extracellular nicotinamide phosphoribosyltransferase: role in disease pathophysiology and as a biomarker
by: Elise Semerena, et al.
Published: (2023-10-01)

Iminosugar-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Potential Anti-Pancreatic Cancer Agents
by: Irene Conforti, et al.
Published: (2023-05-01)

Clickable prodrugs bearing potent and hydrolytically cleavable nicotinamide phosphoribosyltransferase inhibitors
by: Sadrerafi K, et al.
Published: (2018-04-01)

Immunohistochemical Analysis of Nicotinamide Phosphoribosyltransferase Expression in Gastric and Esophageal Adenocarcinoma (AEG)
by: Alexander Arnold, et al.
Published: (2022-12-01)

Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy
by: Peter M LoCoco, et al.
Published: (2017-11-01)

A Nicotinamide Phosphoribosyltransferase Inhibitor, FK866, Suppresses the Growth of Anaplastic Meningiomas and Inhibits Immune Checkpoint Expression by Regulating STAT1
by: Yuxuan Deng, et al.
Published: (2022-04-01)

Advances in NAD-Lowering Agents for Cancer Treatment
by: Moustafa S. Ghanem, et al.
Published: (2021-05-01)

The role of NAMPT in the pathogenesis of psoriasis may be through the regulation of niacin metabolic pathway
by: Fanghua LIU, et al.
Published: (2023-10-01)

Structure-Based Identification and Biological Characterization of New NAPRT Inhibitors
by: Jorge Franco, et al.
Published: (2022-07-01)

Dezocine, An Opioid Analgesic, Exerts Antitumor Effects in Triple-Negative Breast Cancer by Targeting Nicotinamide Phosphoribosyltransferase
by: Chenyang Xue, et al.
Published: (2021-04-01)

Epigenetic regulation of Runx2 transcription and osteoblast differentiation by nicotinamide phosphoribosyltransferase
by: Min Ling, et al.
Published: (2017-05-01)

Association of Nicotinamide Phosphoribosyltransferase (NAMPT) Gene Polymorphisms and of Serum NAMPT Levels with Dilated Cardiomyopathy in a Chinese Population
by: Qingyu Dou, et al.
Published: (2015-09-01)

Nicotinamide Phosphoribosyltransferase‐elevated NAD+ biosynthesis prevents muscle disuse atrophy by reversing mitochondrial dysfunction
by: Yao Zhang, et al.
Published: (2023-04-01)

The NAMPT Inhibitor FK866 Increases Metformin Sensitivity in Pancreatic Cancer Cells
by: Maxime Parisotto, et al.
Published: (2022-11-01)

The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth
by: Kishor Pant, et al.
Published: (2023-02-01)

NAMPT inhibition relieves intestinal inflammation by regulating macrophage activation in experimental necrotizing enterocolitis
by: Qianyang Liu, et al.
Published: (2023-09-01)

AMPK phosphorylates NAMPT to regulate NAD+ homeostasis under ionizing radiation
by: Xiaoyu Liao, et al.
Published: (2022-10-01)

NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance
by: Antonio Lucena-Cacace, et al.
Published: (2019-05-01)

Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy
by: Christine M. Heske
Published: (2020-01-01)

A Versatile Continuous Fluorometric Enzymatic Assay for Targeting Nicotinate Phosphoribosyltransferase
by: Gabriele Minazzato, et al.
Published: (2023-01-01)

Role of secreted extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in prostate cancer progression: Novel biomarker and therapeutic target
by: Belinda L Sun, et al.
Published: (2020-11-01)

A Humanized Monoclonal Antibody Targeting Extracellular Nicotinamide Phosphoribosyltransferase Prevents Aggressive Prostate Cancer Progression
by: Belinda L. Sun, et al.
Published: (2021-12-01)

Insight Into Nicotinamide Adenine Dinucleotide Homeostasis as a Targetable Metabolic Pathway in Colorectal Cancer
by: Giorgia Colombo, et al.
Published: (2021-11-01)

Nicotinamide Phosphoribosyltransferase Inhibitor APO866 Prevents IL-1β-Induced Human Nucleus Pulposus Cell Degeneration via Autophagy
by: Changgui Shi, et al.
Published: (2018-09-01)

Structural Basis of Beneficial Design for Effective Nicotinamide Phosphoribosyltransferase Inhibitors
by: Sei-ichi Tanuma, et al.
Published: (2020-08-01)

Alternative pathway of bile acid biosynthesis contributes to ameliorate NASH after induction of NAMPT/NAD+/SIRT1 axis
by: Na Yang, et al.
Published: (2023-08-01)

CDR1as promotes arrhythmias in myocardial infarction via targeting the NAMPT-NAD+ pathway
by: Yunqi Liu, et al.
Published: (2023-09-01)

SARS-CoV-2 infection dysregulates NAD metabolism
by: Amin Izadpanah, et al.
Published: (2023-06-01)

Molecular properties and regulation of NAD+ kinase (NADK)
by: Shin-ichi Oka, et al.
Published: (2023-02-01)

NAD+ Metabolism Regulates Preadipocyte Differentiation by Enhancing α-Ketoglutarate-Mediated Histone H3K9 Demethylation at the PPARγ Promoter
by: Keisuke Okabe, et al.
Published: (2020-11-01)

Oleate ameliorates palmitate-induced reduction of NAMPT activity and NAD levels in primary human hepatocytes and hepatocarcinoma cells
by: Melanie Penke, et al.
Published: (2017-10-01)

Expression, Function and Bioinformatic Analysis of Nicotinamide Phosphoribosyl Transferase in Colon Cancer
by: TANG Jun, et al.
Published: (2018-12-01)

NAPRT, but Not NAMPT, Provides Additional Support for NAD Synthesis in Esophageal Precancerous Lesions
by: Niannian Wang, et al.
Published: (2022-11-01)

NMNAT1 inhibits axon degeneration via blockade of SARM1-mediated NAD+ depletion
by: Yo Sasaki, et al.
Published: (2016-10-01)

NAD+ depletion enhances reovirus-induced oncolysis in multiple myeloma
by: Barry E. Kennedy, et al.
Published: (2022-03-01)